CN104805066A - 一种葡萄球菌裂解酶及其应用 - Google Patents
一种葡萄球菌裂解酶及其应用 Download PDFInfo
- Publication number
- CN104805066A CN104805066A CN201510252947.6A CN201510252947A CN104805066A CN 104805066 A CN104805066 A CN 104805066A CN 201510252947 A CN201510252947 A CN 201510252947A CN 104805066 A CN104805066 A CN 104805066A
- Authority
- CN
- China
- Prior art keywords
- lyase
- staphylococcus
- clyo
- mrsa
- streptococcus aureus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000856 Lyases Proteins 0.000 title claims abstract description 35
- 102000004317 Lyases Human genes 0.000 title claims abstract description 34
- 241000191940 Staphylococcus Species 0.000 title claims description 22
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 49
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 14
- 238000005336 cracking Methods 0.000 claims abstract description 12
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims abstract description 11
- 229960003085 meticillin Drugs 0.000 claims abstract description 11
- 206010041925 Staphylococcal infections Diseases 0.000 claims abstract description 7
- 238000000338 in vitro Methods 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 3
- 241000894006 Bacteria Species 0.000 claims description 32
- 230000001580 bacterial effect Effects 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 12
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 6
- 238000012797 qualification Methods 0.000 claims description 6
- 108060001084 Luciferase Proteins 0.000 claims description 5
- 239000005089 Luciferase Substances 0.000 claims description 5
- 241001147691 Staphylococcus saprophyticus Species 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims description 3
- 241001033898 Staphylococcus equorum Species 0.000 claims description 3
- 241000191984 Staphylococcus haemolyticus Species 0.000 claims description 3
- 241000192097 Staphylococcus sciuri Species 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 239000013613 expression plasmid Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 229940037649 staphylococcus haemolyticus Drugs 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 241001147736 Staphylococcus capitis Species 0.000 claims description 2
- 241000191973 Staphylococcus xylosus Species 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 238000005342 ion exchange Methods 0.000 claims description 2
- 239000013642 negative control Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
- 239000002953 phosphate buffered saline Substances 0.000 claims 1
- 210000002421 cell wall Anatomy 0.000 abstract description 8
- 230000002147 killing effect Effects 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 3
- 241000295644 Staphylococcaceae Species 0.000 abstract 4
- 239000000126 substance Substances 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000003124 biologic agent Substances 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000013016 damping Methods 0.000 description 6
- 101150084423 femB gene Proteins 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 101150008979 mecA gene Proteins 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 230000001783 staphylolytic effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 239000006158 Baird–Parker agar Substances 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- 108090000988 Lysostaphin Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000751182 Staphylococcus epidermidis ATCC 12228 Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000941 anti-staphylcoccal effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/14—Streptococcus; Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (9)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510252947.6A CN104805066B (zh) | 2015-05-18 | 2015-05-18 | 一种葡萄球菌裂解酶及其应用 |
CA2984582A CA2984582C (en) | 2015-05-18 | 2016-04-12 | Staphylococcus lysin and use thereof |
AU2016263700A AU2016263700B2 (en) | 2015-05-18 | 2016-04-12 | Staphylococcus lyase and use thereof |
PCT/CN2016/079044 WO2016184274A1 (zh) | 2015-05-18 | 2016-04-12 | 一种葡萄球菌裂解酶及其应用 |
US15/571,434 US10626387B2 (en) | 2015-05-18 | 2016-04-12 | Staphylococcus lysin and use thereof |
EP16795761.2A EP3299459B1 (en) | 2015-05-18 | 2016-04-12 | Staphylococcus lyase and use thereof |
DK16795761.2T DK3299459T3 (da) | 2015-05-18 | 2016-04-12 | Staphylococcus-lyase og anvendelse deraf |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510252947.6A CN104805066B (zh) | 2015-05-18 | 2015-05-18 | 一种葡萄球菌裂解酶及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104805066A true CN104805066A (zh) | 2015-07-29 |
CN104805066B CN104805066B (zh) | 2018-04-24 |
Family
ID=53690268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510252947.6A Active CN104805066B (zh) | 2015-05-18 | 2015-05-18 | 一种葡萄球菌裂解酶及其应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10626387B2 (zh) |
EP (1) | EP3299459B1 (zh) |
CN (1) | CN104805066B (zh) |
AU (1) | AU2016263700B2 (zh) |
CA (1) | CA2984582C (zh) |
DK (1) | DK3299459T3 (zh) |
WO (1) | WO2016184274A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016184274A1 (zh) * | 2015-05-18 | 2016-11-24 | 武汉菲吉乐科生物科技有限公司 | 一种葡萄球菌裂解酶及其应用 |
US20170127683A1 (en) * | 2012-05-09 | 2017-05-11 | Raymond Schuch | Biofilm prevention, disruption and treatment with bacteriophage lysin |
CN110592057A (zh) * | 2019-09-27 | 2019-12-20 | 昆明理工大学 | 嵌合裂解酶ILTphg和编码此酶的多核苷酸 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110684760A (zh) * | 2019-09-27 | 2020-01-14 | 吉林大学 | 一种杀灭葡萄球菌的基因工程裂解酶及制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102186878A (zh) * | 2008-08-19 | 2011-09-14 | 拜奥默里克斯公司 | 人工肽聚糖裂解酶和肽聚糖结合蛋白 |
CN103122347A (zh) * | 2013-02-01 | 2013-05-29 | 中国科学院武汉病毒研究所 | 一种杀灭葡萄球菌的裂解酶及其应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004020635A1 (ja) | 2002-08-28 | 2004-03-11 | Techno Network Shikoku Co., Ltd. | バクテリオファージおよび細菌感染症治療剤 |
DE102006061002A1 (de) * | 2006-12-22 | 2008-06-26 | Profos Ag | Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien |
EP2209474A4 (en) * | 2007-10-09 | 2013-07-24 | Sopharmia Inc | BROAD SPECTRUM BETA-LACTAMASE INHIBITORS |
WO2010002959A2 (en) * | 2008-07-03 | 2010-01-07 | The Rockefeller University | A chimeric bacteriophage lysin with activity against staphylococci bacteria |
US8102078B2 (en) * | 2008-07-14 | 2012-01-24 | Sefe, Inc. | Dynamic electrical converter system |
EP2318531A4 (en) * | 2008-07-24 | 2011-11-09 | Us Agriculture | TO RESISTANCE DEVELOPMENT REFRACTORY ANTIMICROBIAL ACTIVE SUBSTANCES |
CA2739717A1 (en) * | 2008-10-10 | 2010-04-15 | Lusomedicamenta, S.A. | Antibacterial phage peptides and methods of use thereof |
KR101016918B1 (ko) * | 2009-01-08 | 2011-02-25 | 주식회사 인트론바이오테크놀로지 | 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질 |
EP2338916A1 (en) * | 2009-12-23 | 2011-06-29 | Hyglos Invest GmbH | Chimeric polypeptides and their use in bacterial decoloniation |
EP2397548A1 (en) * | 2010-06-18 | 2011-12-21 | Hyglos Invest GmbH | Methods of generating and screening for lytic chimeric polypeptides |
EP3252155A1 (en) * | 2011-04-21 | 2017-12-06 | The Rockefeller University | Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria |
US8790639B2 (en) * | 2012-03-28 | 2014-07-29 | The United States Of America, As Represented By The Secretary Of Agriculture | Enhanced antimicrobial lytic activity of a chimeric Ply187 endolysin |
KR20230135161A (ko) * | 2012-05-09 | 2023-09-22 | 콘트라펙트 코포레이션 | 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료 |
CN102676490B (zh) * | 2012-05-21 | 2013-07-31 | 江苏省农业科学院 | 一种金黄色葡萄球菌噬菌体溶壁酶及其制备方法和应用 |
US8980614B2 (en) * | 2012-09-06 | 2015-03-17 | The United States Of America, As Represented By The Secretary Of Agriculture | Staphylococcus haemolyticus prophage φSH2 endolysin is lytic for Staphylococcus aureus |
US9872893B2 (en) * | 2014-07-10 | 2018-01-23 | University Of Maryland College Park | Endolysins active against Staphylococcus bacteria, pharmaceutical compositions, and methods relating thereto |
CN104726439B (zh) * | 2015-04-13 | 2017-11-14 | 武汉菲吉乐科生物科技有限公司 | 一种广谱的链球菌裂解酶及其应用 |
CN104805066B (zh) * | 2015-05-18 | 2018-04-24 | 武汉菲吉乐科生物科技有限公司 | 一种葡萄球菌裂解酶及其应用 |
AU2016324307B2 (en) * | 2015-09-17 | 2021-10-21 | Contrafect Corporation | Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby |
WO2019113096A1 (en) * | 2017-12-05 | 2019-06-13 | BioPlx, Inc. | Methods and compositions to prevent microbial infection |
-
2015
- 2015-05-18 CN CN201510252947.6A patent/CN104805066B/zh active Active
-
2016
- 2016-04-12 AU AU2016263700A patent/AU2016263700B2/en active Active
- 2016-04-12 WO PCT/CN2016/079044 patent/WO2016184274A1/zh active Application Filing
- 2016-04-12 EP EP16795761.2A patent/EP3299459B1/en active Active
- 2016-04-12 US US15/571,434 patent/US10626387B2/en active Active
- 2016-04-12 CA CA2984582A patent/CA2984582C/en active Active
- 2016-04-12 DK DK16795761.2T patent/DK3299459T3/da active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102186878A (zh) * | 2008-08-19 | 2011-09-14 | 拜奥默里克斯公司 | 人工肽聚糖裂解酶和肽聚糖结合蛋白 |
CN103122347A (zh) * | 2013-02-01 | 2013-05-29 | 中国科学院武汉病毒研究所 | 一种杀灭葡萄球菌的裂解酶及其应用 |
Non-Patent Citations (3)
Title |
---|
TANG,F ET AL.: ""Streptococcus phage phi891591,complete genome"", 《GENBANK》 * |
杨航: ""噬菌体裂解酶的功能与应用研究"", 《豆丁,WWW.DOCIN.COM/P-891983909.HTML?DOCFROM=RRELA》 * |
杨航等: ""裂解酶治疗的研究进展与应用前景"", 《微生物学通报》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170127683A1 (en) * | 2012-05-09 | 2017-05-11 | Raymond Schuch | Biofilm prevention, disruption and treatment with bacteriophage lysin |
US11524046B2 (en) | 2012-05-09 | 2022-12-13 | Contrafect Corporation | Biofilm prevention, disruption and treatment with bacteriophage lysin |
WO2016184274A1 (zh) * | 2015-05-18 | 2016-11-24 | 武汉菲吉乐科生物科技有限公司 | 一种葡萄球菌裂解酶及其应用 |
US10626387B2 (en) | 2015-05-18 | 2020-04-21 | Phagelux, Inc. | Staphylococcus lysin and use thereof |
CN110592057A (zh) * | 2019-09-27 | 2019-12-20 | 昆明理工大学 | 嵌合裂解酶ILTphg和编码此酶的多核苷酸 |
CN110592057B (zh) * | 2019-09-27 | 2022-01-28 | 昆明理工大学 | 嵌合裂解酶ILTphg和编码此酶的多核苷酸 |
Also Published As
Publication number | Publication date |
---|---|
WO2016184274A1 (zh) | 2016-11-24 |
AU2016263700A1 (en) | 2017-11-30 |
AU2016263700B2 (en) | 2021-12-02 |
DK3299459T3 (da) | 2021-01-11 |
CN104805066B (zh) | 2018-04-24 |
CA2984582A1 (en) | 2016-11-24 |
EP3299459A4 (en) | 2018-12-19 |
CA2984582C (en) | 2022-07-12 |
US20180291357A1 (en) | 2018-10-11 |
EP3299459A1 (en) | 2018-03-28 |
EP3299459B1 (en) | 2020-10-07 |
US10626387B2 (en) | 2020-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104726439B (zh) | 一种广谱的链球菌裂解酶及其应用 | |
CN106282127B (zh) | 新的噬菌体、其组合物以及它们的制备方法和应用 | |
CN112143747B (zh) | 一种噬菌体裂解酶及其基因、基因重组表达载体与应用 | |
CN103122347B (zh) | 一种杀灭葡萄球菌的裂解酶及其应用 | |
CN104593346B (zh) | 一种来源于副溶血弧菌噬菌体的内溶素及其应用 | |
CN107779439A (zh) | 新的葡萄球菌噬菌体及其组合物、制备方法和应用 | |
CN105200028A (zh) | 来源于副溶血弧菌噬菌体的内溶素及其应用 | |
CN104805066A (zh) | 一种葡萄球菌裂解酶及其应用 | |
CN107058265A (zh) | 铜绿假单胞菌噬菌体裂解酶及应用 | |
CN104830825A (zh) | 一种来源于沙门氏菌噬菌体的内溶素及其应用 | |
CN105238773A (zh) | 一种抗葡萄球菌的宽谱噬菌体嵌合裂解酶及其制备方法与应用 | |
CN104962572A (zh) | 一种嗜水气单胞菌外膜蛋白基因原核表达蛋白的制备方法 | |
CN102198265B (zh) | 应用噬菌体裂解酶降解猪链球菌生物被膜的方法 | |
Zhu et al. | Correlation between the distribution pattern of virulence genes and virulence of Aeromonas hydrophila strains | |
CN107177580A (zh) | 一种广谱新型嵌合裂解酶GBS‑PlySb及其编码基因和应用 | |
CN107252475A (zh) | 天然宿主防御肽Alligatorin4的应用 | |
CN104961811A (zh) | 嗜水气单胞菌外膜蛋白基因原核表达蛋白及其应用 | |
Leite et al. | Lytic bacteriophages as a potential alternative to control Staphylococcus aureus | |
CN104726429A (zh) | 一种具有增强的抑菌效果的噬菌体裂解酶 | |
CN104561267A (zh) | 检测罗非鱼无乳链球菌的环介导等温扩增反应引物 | |
CN103387992A (zh) | 编码重组猪β-防御素-1的基因及猪β-防御素-1的制备方法 | |
CN104987367A (zh) | 人工抗菌肽pr39-r1t的制备方法及其应用 | |
CN107670023A (zh) | V12cbd蛋白及其编码基因的一种新用途 | |
CN103467580B (zh) | 人工抗菌肽ma-d4的制备方法及其应用 | |
CN101565462B (zh) | 大黄鱼bpi-bn蛋白质、引物及其在制备抗生素药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Wuhan Faye Gile C biological science and Technology Co.,Ltd. Office Document name: Notification that Application Deemed not to be Proposed |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160405 Address after: 430075 A7 Exhibition Center of biomedicine Park, 858 hi tech Avenue, East Lake New Technology Development Zone, Wuhan, Hubei Applicant after: WUHAN PHAGELUX BIO-TECH Co.,Ltd. Address before: 430075, B7 building, Optics Valley biological city, 666 hi tech Avenue, East Lake Development Zone, Hubei, Wuhan Applicant before: Wuhan Phagelux Bio-tech Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201125 Address after: Co services Cayman limited, P.O. Box 10008 willow house, cricket square, Grand Cayman Islands Patentee after: Figelok Co.,Ltd. Address before: 430075 A7 Exhibition Center of biomedicine Park, 858 hi tech Avenue, East Lake New Technology Development Zone, Wuhan, Hubei Patentee before: Wuhan Phagelux Bio-tech Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231023 Address after: Room 201, 1012 College Road, Dover, Delaware, United States Patentee after: Targeted Antibiotics Biopharmaceutical Technology Co.,Ltd. Address before: Co services Cayman limited, P.O. Box 10008 willow house, cricket square, Grand Cayman Islands Patentee before: Figelok Co.,Ltd. |